

Jordi Barretina Ginesta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4060995/jordi-barretina-ginesta-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56 papers	19,200 citations	40 h-index	66 g-index
66 ext. papers	22,930 ext. citations	17.1 avg, IF	5.1 L-index

#	Paper	IF	Citations
56	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. <i>Nature Communications</i> , 2021 , 12, 6946	17.4	1
55	E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. <i>Oncogene</i> , 2021 , 40, 6614-6626	9.2	0
54	Whole-Brain Dynamics in Aging: Disruptions in Functional Connectivity and the Role of the Rich Club. <i>Cerebral Cortex</i> , 2021 , 31, 2466-2481	5.1	3
53	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. <i>Mechanisms of Ageing and Development</i> , 2020 , 189, 111257	5.6	6
52	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. <i>International Journal of Cancer</i> , 2019 , 145, 3321-3333	7.5	5
51	Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , 2019 , 569, 503-508	50.4	962
50	The landscape of cancer cell line metabolism. <i>Nature Medicine</i> , 2019 , 25, 850-860	50.5	188
49	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. <i>Oncogene</i> , 2019 , 38, 6399-6413	9.2	79
48	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. <i>Nature Communications</i> , 2018 , 9, 4181	17.4	45
47	EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. <i>Cancer Research</i> , 2016 , 76, 1591-602	10.1	90
46	Identification of ALK gene alterations in urothelial carcinoma. <i>PLoS ONE</i> , 2014 , 9, e103325	3.7	8
45	An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. <i>Cell</i> , 2013 , 154, 1151-1161	56.2	392
44	Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013 , 45, 1386-91	36.3	192
43	Genomic medicine frontier in human solid tumors: prospects and challenges. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1874-84	2.2	90
42	NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1906-17	6.1	58
41	Melanoma genome sequencing reveals frequent PREX2 mutations. <i>Nature</i> , 2012 , 485, 502-6	50.4	555
40	Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. <i>Clinical Cancer Research</i> , 2012 , 18, 4997-5007	12.9	195

39	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. <i>Nature</i> , 2012 , 483, 603-7	50.4	4648
38	Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. <i>Cancer Research</i> , 2012 , 72, 4383-93	10.1	204
37	Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. <i>Nature</i> , 2011 , 476, 346-50	50.4	1063
36	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011 , 43, 964-968	36.3	242
35	Advances in sarcoma genomics and new therapeutic targets. <i>Nature Reviews Cancer</i> , 2011 , 11, 541-57	31.3	291
34	Nuclear factor I/B is an oncogene in small cell lung cancer. <i>Genes and Development</i> , 2011 , 25, 1470-5	12.6	118
33	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 12372-7	11.5	321
32	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010 , 463, 899-905	50.4	2590
31	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010 , 468, 968-72	50.4	1162
30	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010 , 42, 715-21	36.3	521
29	Integrative analysis of the melanoma transcriptome. <i>Genome Research</i> , 2010 , 20, 413-27	9.7	216
28	Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. <i>International Journal of Cancer</i> , 2010 , 127, 2718-22	7.5	57
27	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2009 , 8, 2042-50	4.6	65
26	Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. <i>Cancer Cell</i> , 2009 , 16, 115-25	24.3	366
25	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. <i>Nature Genetics</i> , 2009 , 41, 882-4	36.3	550
24	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1727-40	15.9	205
23	CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. <i>Nature</i> , 2008 , 455, 547-51	50.4	519
22	Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. <i>Cancer Research</i> , 2008 , 68, 6779-88	10.1	463

21	CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. <i>Molecular Cell</i> , 2008 , 32, 718-26	17.6	104
20	Functional copy-number alterations in cancer. <i>PLoS ONE</i> , 2008 , 3, e3179	3.7	129
19	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007 , 39, 347-51	36.3	847
18	Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20007-12	11.5	812
17	R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. <i>Journal of Leukocyte Biology</i> , 2004 , 76, 804-11	6.5	42
16	Immunological and virological study of enfuvirtide-treated HIV-positive patients. <i>Aids</i> , 2004 , 18, 1673-82	3.5	29
15	High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. <i>Journal of Biological Chemistry</i> , 2004 , 279, 51305-14	5.4	82
14	Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events. <i>Virology</i> , 2003 , 305, 318-29	3.6	60
13	Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression. <i>Journal of Virology</i> , 2003 , 77, 4389-95	6.6	23
12	Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. <i>Antiviral Therapy</i> , 2003 , 8, 155-61	1.6	7
11	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. <i>Antiviral Therapy</i> , 2003 , 8, 155-161	1.6	14
10	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. <i>Antiviral Therapy</i> , 2003 , 8, 1-8	1.6	16
9	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. <i>Antiviral Research</i> , 2002 , 53, 1-8	10.8	29
8	Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. <i>EMBO Journal</i> , 2002 , 21, 4070-80	13	116
7	Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 27-38	1.6	12
6	CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro. <i>Virology</i> , 2001 , 285, 356-65	3.6	19
5	Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. <i>Journal of Experimental Medicine</i> , 2001 , 194, 1097-110	16.6	135
4	Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. <i>Journal of Virology</i> , 2001 , 75, 10319-25	6.6	113

3	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. <i>Aids</i> , 2001 , 15, 1890-2	3.5	12
2	The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 51-6	5.9	58
1	Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 627-34	1.6	32